Table 1.
Component calculations for ASCO NHB scores and ESMO MCBS grades for concurrent and maintenance bevacizumab
| OCEANS | GOG 213 | |
|---|---|---|
| ASCO NHB | ||
| Clinical Benefit | 42 | 30 |
| Toxicity | (−)7 | (−)4 |
| Tail of the curve | 0 | - |
| Palliation of symptoms | - | - |
| TFI | - | - |
| QOL | 0 | 0 |
| Final NHB score | 34 | 26 |
| ESMO MCBS | ||
| Clinical Benefit | 3 | 3 |
| Toxicity | 0 | 0 |
| QOL | 0 | 0 |
| Final adjustments | (−)1 | (−)1 |
| Final MCBS grade | 2 | 2 |
ASCO = American Society of Clinical Oncology; NHB = Net Health Benefit; ESMO = European Society of Medical Oncology; MCBS = Magnitude of Clinical Benefit Scale; QOL = quality of life; TFI = treatment-free interval